Helix BioMedix
Helix BioMedix officials announce the latest developments
Published in Lab Law Weekly, February 16th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Helix BioMedix.
Report 1: Helix BioMedix, Inc., (HXBM.OB), a developer of bioactive peptides, announced financial results for the 3- and 9-month periods ended September 30, 2006 with a third quarter net loss of $870,507, or $0.04 net loss per share, compared to a net loss of $797,951, or $0.04 net loss per share, for the comparable period in 2005.
Revenue for the 3-month period ended September 30, 2006 was $18,841, derived from licensing revenue and the sale of peptides....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2007-02-16)
More Articles from Lab Law Weekly
- Business Update
Biomoda retains Northport for government relations and public affairs services - Business Update
Coalition America to offer repricing service for dental claims in 2007 - Business Update
EDS awarded $91.7 million Kansas Medicaid extension to provide fiscal agent services into 2011 - Business Update
Peregrine Pharmaceuticals establishes wholly owned subsidiary in China - Business Update
SPSS releases updated version of enterprise data mining software - Drug Safety
Consumers Union says drug industry, U.S. FDA user-fee deal fails to fix drug safety crisis - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
